Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years

BACKGROUD: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Byung Wook, Kim, Chang Oh, Izu, Allen, Arora, Ashwani Kumar, Heijnen, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312896/
https://www.ncbi.nlm.nih.gov/pubmed/30600653
http://dx.doi.org/10.3947/ic.2018.50.4.301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312896/
https://www.ncbi.nlm.nih.gov/pubmed/30600653
http://dx.doi.org/10.3947/ic.2018.50.4.301

Ejemplares similares